Veracyte, Inc. research snapshot
VCYT AI stock analysis reads Veracyte as a profitable precision oncology diagnostics company that reported a strong Q2 and raised 2026 guidance, then saw its stock drop about 22% in one session on profit taking and a modest Decipher volume cut. At the August 3, 2026 cutoff, the July 31 close was $46.32, market capitalization was about $3.72 billion, and the page treats forward scenarios rather than price promises. This is informational research and not investment advice.
Current price
$46.32
Market cap
$3.72 billion
AI score
56 / 100
Rating
Profitable growth, elevated valuation, post-earnings pullback
Trend status
Long-term uptrend intact but the stock broke sharply below the 50-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Veracyte sells genomic diagnostic tests for thyroid, prostate, breast, bladder, and lung cancer using proprietary classifiers, RNA sequencing, and a new whole-genome MRD platform. | High |
| Moat | The moat comes from proprietary classifiers, large clinical validation data sets, payer reimbursement infrastructure, and guideline-backed adoption. It is moderate and durable, not fortress-like. | Medium |
| Management | Management delivered a Q2 beat, launched Prosigna and TrueMRD, and raised 2026 revenue guidance. Execution is strong, though new-test reimbursement is still developing. | Medium-high |
| Financial trend | Revenue grew 15% in Q2 2026 to $150.3M with TTM revenue of $561.9M. The company is GAAP profitable with TTM net income of about $114M, strong cash generation, and net cash of about $445M. | High |
| Valuation | The stock trades at about 33x TTM earnings, 26x forward earnings, and 6.6x sales after the pullback. Growth is priced in but the multiple is no longer extreme after the July 31 drop. | Medium |
| Technical trend | The stock broke below the $53.31 50-day average on heavy volume and sits above the $41.89 200-day average. Use live chart confirmation before acting. | Medium |
| Risk level | Key risks are reimbursement pressure, the NCCN-related low-risk Decipher slowdown, new-test adoption uncertainty, competition, and high volatility with a beta near 1.9. | Medium |
| AI confidence | High confidence on the fundamentals snapshot and quote math. Lower confidence on near-term price direction after a large one-day move. | High |
| Investment certainty | Medium certainty on the business trajectory, low certainty on entry timing because the page is a framework, not personalized advice. | Medium |
VCYT AI stock forecast
The VCYT AI stock forecast uses scenario ranges around the $46.32 July 31 close rather than a point target. The bullish case needs the newly launched Prosigna and TrueMRD tests to scale with reimbursement, the base case assumes mid-teens revenue growth at current margins, and the bearish case assumes reimbursement pressure or growth deceleration compresses the multiple.
$70.00 to $90.00
More likely if Prosigna gains broad Medicare and commercial coverage, TrueMRD expands beyond bladder cancer, Decipher returns to double-digit growth, and the stock reclaims the 50-day average with rising volume. Analyst targets cluster around $62 to $70, with the high end near $70.
$50.00 to $68.00
More likely if revenue grows at the raised 2026 guidance of 14% to 15%, adjusted EBITDA margin stays above 26%, and the multiple settles near current levels while investors watch Prosigna reimbursement decisions.
$32.00 to $46.00
More likely if reimbursement pressure intensifies, low-risk Decipher stays weak, new-test launches disappoint, gross margin faces headwinds from unreimbursed Prosigna volume, or the stock closes below the 200-day average after the data cutoff.
VCYT AI technical analysis
VCYT AI technical analysis starts from the $46.32 close on July 31, 2026. Because this static page does not fetch request-time chart data, moving averages and momentum should be confirmed in a live chart before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $46.32 | Close on July 31, 2026, after a roughly 22% single-session drop on about 6.0 million shares versus a typical volume near 1.25 million. |
| 52-week range | $22.92 to $60.91 | The range brackets a strong run-up through late June followed by the July 31 selloff. |
| 50-day moving average | $53.31 | The stock closed below this average on July 31. A reclaim would signal renewed buyer control. |
| 200-day moving average | $41.89 | The stock still trades above the 200-day average, so the longer-term trend is not yet broken. |
| Near support | $43.00 to $45.00 | The July 31 low was $43.52. This zone is the first demand area to watch below the close. |
| Deeper support | $40.00 to $42.00 | Around the 200-day moving average. A decisive close below here would weaken the long-term uptrend. |
| Near resistance | $50.00 to $53.50 | The 50-day average near $53.31 and round-number selling around $50 form the first resistance band. |
| Momentum | Oversold after the drop | The RSI fell to about 34, which can precede short-term stabilization but is not a buy signal by itself. |
| Volume | Heavy selloff volume | July 31 volume of about 6.0 million shares was roughly five times the average, showing aggressive selling. |
| Volatility | High | Beta is near 1.9, so the stock moves about twice as much as the market. |
| Invalidation | Close below $40.00 | A close below the $40 to $42 support band, including the 200-day average, would invalidate the bullish structure. |
VCYT AI trading strategy
The VCYT AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with live price data, position sizing, stop levels, and fresh filings or reimbursement news.
Wait for VCYT to reclaim and hold the $50 to $53 resistance band, ideally with a Prosigna reimbursement catalyst, before considering an uptrend continuation setup.
A failure to hold the reclaimed resistance or a close below $43 would invalidate the setup.
If VCYT stabilizes near the $43 to $45 support zone with declining volume, compare price action with the next Prosigna and TrueMRD adoption data, gross margin, and guidance before acting.
Do not average down without a predefined maximum loss and a fresh review of reimbursement and competitive risk.
Track the evidence that matters for precision oncology diagnostics: Prosigna and TrueMRD reimbursement decisions, Decipher low-risk volume, gross margin trends, adjusted EBITDA margin, and cash generation.
Reduce confidence when price moves are driven by headlines without matching financial evidence.
Investment research summary
Veracyte sells genomic diagnostic tests that help doctors classify thyroid nodules, assess prostate and bladder cancer risk, characterize breast cancer subtypes, and now monitor recurrence through a whole-genome MRD platform.
The moat is built from proprietary genomic classifiers, clinical validation data that supports payer reimbursement, and strong adoption of Afirma and Decipher. Barriers are moderate because liquid biopsy and sequencing competitors keep pushing forward.
The thesis can fail if Medicare and commercial reimbursement pressure builds, if the NCCN-related low-risk Decipher slowdown persists, if Prosigna and TrueMRD adoption stalls, or if the nCounter and whole-genome platforms face competition from cheaper alternatives.
Management delivered a Q2 beat, launched Prosigna LDT and TrueMRD for MIBC, secured Medicare coverage for TrueMRD, and raised 2026 revenue guidance to $590M to $596M. The main open item is Prosigna Medicare pricing.
Precision oncology diagnostics sits in a secular growth trend driven by aging populations, rising cancer incidence, targeted therapies that need genomic profiling, and the fast-growing minimal residual disease (MRD) market.
At about 33x trailing earnings and 6.6x sales after the pullback, the valuation still assumes sustained growth. The margin of safety improved versus the pre-drop price but remains thin if growth decelerates or the multiple contracts.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VCYT price | $46.32 | Yahoo Finance and StockAnalysis quote snapshot | August 3, 2026 |
| Market capitalization | $3.72 billion, verified as $46.32 x 80.39M shares | financial_rigor.py market cap verification | August 3, 2026 |
| Exchange | NasdaqGM | Yahoo Finance and StockAnalysis profile | August 3, 2026 |
| Revenue (TTM) | $561.90M | StockAnalysis financials (Fiscal.ai) | August 3, 2026 |
| Q2 2026 revenue | $150.3M, up 15% year over year | Veracyte Q2 2026 press release | August 3, 2026 |
| Net income (TTM) | $114.48M | StockAnalysis statistics (S&P Global Market Intelligence) | August 3, 2026 |
| Cash and investments | $485.23M as of June 30, 2026 | Veracyte Q2 2026 balance sheet and StockAnalysis | August 3, 2026 |
| Net cash | $445.13M, or about $5.54 per share | StockAnalysis statistics | August 3, 2026 |
| Free cash flow (TTM) | $165.99M | StockAnalysis statistics (S&P Global Market Intelligence) | August 3, 2026 |
| 2026 revenue guidance | $590M to $596M, up 14% to 15% | Veracyte Q2 2026 press release | August 3, 2026 |
| Analyst consensus | Buy with an average price target of $62.33 | StockAnalysis forecast (S&P Global Market Intelligence) | August 3, 2026 |
This VCYT AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 3, 2026, may be incomplete, and can be wrong if new filings, market prices, reimbursement decisions, company events, or macro conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
